Bristol-Myers Squibb Surges Into Year-End: Why BMY Still Looks Undervalued

Bristol-Myers Squibb ( BMY ) has come on strong to finish off 2025. I was bullish on the now $110 billion market cap healthcare sector stock back in the third quarter , and shares have returned a solid 18%, dividend included, since then. That’s more thanFreelance Financial Writer | Investments | Markets | Personal Finance | RetirementI create written content used in various formats including articles, blogs, emails, and social media for financial advisors and investment firms in a cost-efficient way. My pas ...